DNTH Live signals | Maximize Profits with Getagraph.com

BUY 128834 min ago

@ $22.91

Issued: 8 Feb 2024 @ 12:13

Return: 4.93%

Previous signal: Feb 7 - 15:54

Previous signal: Sell

Return: -4.78 %

Live Chart Being Loaded With Signals

Commentary (7 May 2024 @ 16:00):

Stats
Today's Volume	61 248.00
Average Volume	171 872
Market Cap	705.50M
EPS	$0 ( 2024-03-21 )
Next earnings date	( $-0.430 ) 2024-06-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.84
ATR14	$0.0790 (0.33%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-01	Fairmount Funds Management Llc	Buy	58 857	Common Stock
2024-04-01	Fairmount Funds Management Llc	Sell	58 857	Common Stock
2024-01-24	Carr Edward	Buy	80 000	Stock Option (Right to Buy)
2024-01-24	Veness Adam M	Buy	110 000	Stock Option (Right to Buy)
2024-01-24	Randhawa Simrat	Buy	120 000	Stock Option (Right to Buy)

INSIDER POWER
97.86
Last 18 transactions
Buy: 6 045 948 \| Sell: 58 857

Volume Correlation

Long: 0.21 (neutral)

Short: -0.61 (weak negative)

Signal:(51.429) Neutral

Dianthus Therapeutics, Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Dianthus Therapeutics, Correlation - Currency/Commodity

0.18
( neutral )

0.20
( neutral )

0.00
( neutral )

0.56
( weak )

-0.47
( neutral )

0.45
( neutral )

Dianthus Therapeutics, Financials

Annual	2023
Revenue:	$2.83M
Gross Profit:	$2.47M (87.44 %)
EPS:	$-8.45

FY	2023
Revenue:	$2.83M
Gross Profit:	$2.47M (87.44 %)
EPS:	$-8.45

FY	2022
Revenue:	$6.42M
Gross Profit:	$6.27M (97.71 %)
EPS:	$-32.57

Financial Reports:

No articles found.

Dianthus Therapeutics,

Dianthus Therapeutics, Inc. operates as a clinical-stage biotechnology company that designs, develops, and delivers novel monoclonal antibodies for people living with severe autoimmune and inflammatory diseases. It develops DNTH103 that is in phase 1 clinical trails in patients with generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was incorporated in 2015 and is based in New York, New York.